173 related articles for article (PubMed ID: 35447552)
21. Serial Cell-Free DNA Sequencing in
Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
[TBL] [Abstract][Full Text] [Related]
22. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
23. Entrectinib: First Global Approval.
Al-Salama ZT; Keam SJ
Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
[TBL] [Abstract][Full Text] [Related]
24. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
[TBL] [Abstract][Full Text] [Related]
25. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
26. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
28. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
29. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
30. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
González-Sales M; Djebli N; Meneses-Lorente G; Buchheit V; Bonnefois G; Tremblay PO; Frey N; Mercier F
Cancer Chemother Pharmacol; 2021 Dec; 88(6):997-1007. PubMed ID: 34536094
[TBL] [Abstract][Full Text] [Related]
32. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
[TBL] [Abstract][Full Text] [Related]
33. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
34. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Dziadziuszko R; Hung T; Wang K; Choeurng V; Drilon A; Doebele RC; Barlesi F; Wu C; Dennis L; Skoletsky J; Woodhouse R; Li M; Chang CW; Simmons B; Riehl T; Wilson TR
Mol Oncol; 2022 May; 16(10):2000-2014. PubMed ID: 35338679
[TBL] [Abstract][Full Text] [Related]
35. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
[TBL] [Abstract][Full Text] [Related]
36. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
37. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G; Bentley D; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Brink A; Djebli N; Mercier F; Buchheit V; Phipps A
Invest New Drugs; 2021 Jun; 39(3):803-811. PubMed ID: 33462752
[TBL] [Abstract][Full Text] [Related]
39. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
40. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]